As the pandemic of obesity is growing, a variety of animal models have been generated to study the mechanisms underlying the increased adiposity and development of metabolic disorders. Tamoxifen (Tam) is widely used to activate Cre recombinase that spatiotemporally controls target gene expression and regulates adiposity in laboratory animals. However, a critical question remains as to whether Tam itself affects adiposity and possibly confounds the functional study of target genes in adipose tissue. Here we administered Tam to Cre-absent forkhead box O1 (FoxO1) floxed mice (f-FoxO1) and insulin receptor substrate Irs1/Irs2 double floxed mice (df-Irs) and found that Tam induced approximately 30% reduction ($P<0.05$) in fat mass with insignificant change in body weight. Mechanistically, Tam promoted reactive oxygen species (ROS) production, apoptosis and autophagy, which was associated with downregulation of adipogenic regulator peroxisome proliferator-activated receptor gamma and dedifferentiation of mature adipocytes. However, normalization of ROS potently suppressed Tam-induced apoptosis, autophagy and adipocyte dedifferentiation, suggesting that ROS may account, at least in part, for the changes. Importantly, Tam-induced ROS production and fat mass reduction lasted for 4–5 weeks in the f-FoxO1 and df-Irs mice. Our data suggest that Tam reduces fat mass via boosting ROS, thus making a recovery period crucial for posttreatment study.

Cell Death and Disease (2015) 6, e1586; doi:10.1038/cddis.2014.553; published online 8 January 2015
administration is essential to understand the functions of target genes using Tam-induced knockout mice.

**Results**

**Tam induced fat mass reduction in mice.** To test the effect of Tam on fat mass, we conducted a 5-day I.P. administration of Tam (1 mg/20 g body weight) on forkhead box O1 (FoxO1) floxed mice bearing no Cre recombinase (f-FoxO1) by following a standard protocol established previously. Two weeks after Tam administration, the body fat was reduced by 34% ($P<0.05$) in f-FoxO1 mice (Figure 1a). To validate the findings, we treated insulin receptor substrate 1 (Irs1) and Irs2 double floxed mice without Cre recombinase (df-Irs) in a similar way, and found that fat mass was also significantly reduced (26%, $P<0.05$; Supplementary Figure S1A). However, the changes in body weight were insignificant between vehicle (sunflower oil) control and the treatment groups (Figure 1b; Supplementary Figure S1B). Monitoring of the kinetics of fat mass change suggested that the reduction was persistent till week 5 (week 4 in df-Irs mice), after which the fat percentage was comparable to the pretreatments (Figure 1a; Supplementary Figure S1A). In line with this finding, the weight of epididymal white adipose tissue (eWAT) was significantly reduced in Tam-treated f-FoxO1 mice at week 2, while there was no significant difference at week 6 (Figures 1c and d). By contrast, injection of the vehicle caused indiscernible change in the body fat mass (Figure 1a; Supplementary Figure S1A). Therefore, the reduction of fat mass in mice arose primarily from Tam treatment. Given that both mouse models shared this phenotype, we used f-FoxO1 mice for the following mechanistic study.

**Tam promoted apoptosis and autophagy in adipose tissue.** The regulators of apoptosis and autophagy were implicated in the regulation of fat mass. To examine whether Tam had effects on apoptosis and autophagy, we used eWAT at weeks 2 and 6 after Tam administration and analyzed the mediators of apoptosis and autophagy—the activated or cleaved caspase 3 (Cas3) and microtubule-associated protein 1A/1B-light chain 3-phosphatidylethanolamine conjugate (LC3), respectively. As shown in Figures 2a and b, Tam treatment increased the level of Cas3(c) by 6.8-fold ($P<0.0001$) and the autophagosomal marker LC3-II by 1.9-fold ($P<0.05$) at week 2. However, these changes were largely reversed at week 6 and showed no statistical significance (Figures 2c and d).

**Figure 1** Tam reduced fat mass in f-FoxO1 mice. (a) The kinetics of fat mass regulation after 5-day administration of Tam. (b) Measurement of body weight before Tam treatment (pre-Tam), 2 weeks (2wk) and 6 weeks (6wk) after Tam injection. (c) The weight of epididymal adipose tissue (eWAT) at week 2 in mice treated with Tam. (d) The weight of eWAT at week 6 in mice treated with Tam. $n=4$–6; $^*P<0.05$; $^{**}P<0.01$; NS, not significant.
oxidative stress. Tam treatment upregulated HO1 protein levels in adipose tissue by over 7-fold ($P < 0.0001$) in mice at week 2; however, at week 6, the HO1 abundance in the treated mice was comparable to that in untreated mice, showing no statistical significance (Figures 3a and b). Interestingly, the HO1 levels in untreated mice were higher at week 6 than at week 2, supporting the notion that HO1 expression increases with age.\textsuperscript{30,31}

Measurement of ROS
levels in adipose tissue indicated a 2.3-fold elevation in Tam-treated mice than in vehicle-treated mice at week 2 (Figure 3c), but they became statistically insignificant at week 6 (Figure 3d). Of note, the upregulation and downregulation of ROS and HO1 levels seems to coincide well with the changes in Cas3(c), LC3-II and fat mass (Figures 1–3).

Antioxidant abolished Tam-induced ROS, apoptosis and autophagy. To map the interaction between ROS and other Tam-induced cellular events, we treated 3T3L1 adipocytes with Tam combined with a potent ROS-scavenger NAC. As observed in adipose tissue, Tam induced significant upregulation of HO1 in 3T3L1 adipocytes, and the effect was dose dependent in the tested range of 0–128 μM (Supplementary Figure S2). Tam also promoted ROS production by 2.5-fold ($P < 0.01$) in 3T3L1 adipocytes (Figure 4a) and significantly upregulated the apoptosis regulators Cas3(c) and autophagosomal marker LC3-II (Figures 4b and c). However, inclusion of NAC in the treatments suppressed Tam-induced elevation of ROS and HO1 and normalized the protein levels of Cas3(c) and LC3-II (Figures 4a–c).

Antioxidant reversed Tam-induced reduction in cell density and adipocyte population. Because alteration in adipocyte number affects adiposity, we asked whether Tam treatment influenced cell density. Compared with the vehicle-treated adipocytes, Tam-treated cells showed a significant decrease in cell density (24%, $P < 0.05$), consistent with the upregulation of apoptotic marker (Figures 5a, b and d). Interestingly, the population of lipid-droplet-containing cells (i.e., mature adipocytes) also declined (36%, $P < 0.05$), implying a process of ‘dedifferentiation’ might be induced by Tam (Figures 5a, b and e). Regardless, addition of the ROS-scavenger NAC largely restored the cell density and population of mature adipocytes (Figures 5c and e).

Antioxidant reversed Tam-induced downregulation of peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ is a key regulator of adipogenesis (de novo generation of mature adipocytes) and adipocyte dedifferentiation. The observation of reduced population of mature adipocytes after Tam treatment prompted us to analyze the effect of Tam on PPARγ. As shown in Figure 6a, PPARγ protein levels were reduced by 74% ($P < 0.01$) in Tam-treated adipocytes. However, co-treatment of the adipocytes with Tam and NAC significantly restored PPARγ level. These data suggest that Tam may regulate adipogenesis or population of mature adipocytes through ROS-mediated downregulation of PPARγ. Consistent with this hypothesis, we found that the PPARγ levels were dramatically decreased (69%, $P < 0.01$) in the adipose tissues of Tam-treated mice at week 2 (Figure 6b), which is accompanied by elevation of ROS and HO1 (Figures 3a–c). At week 6 when ROS and HO1 levels returned to normal (Figures 3a, b and d); however, the abundance of PPARγ also returned to the values comparable to those in the control mice (Figure 6c). In addition, the reversal of ROS overproduction and PPARγ...
suppression was accompanied by normalization of fat mass at week 6 (Figures 1, 3 and 6 Supplementary Figure S1).

Discussion

Tam has been widely used to activate inducible Cre recombinase and knockout target genes in mechanistic studies of adipose development and metabolic homeostasis.\(^8,^{11,12,38-41}\) However, the effect of Tam administration on adipocytes and adipose tissue has not been investigated to the best of our knowledge. In this study, we chose to use f-FoxO1 bearing no Cre recombinase for Tam treatment, aiming to rule out the effect of Cre activation (or gene deletion) on fat mass. We found that a 5-day administration of Tam led to a significant reduction of fat mass in mice, which lasted for 4–5 weeks after the last injection. The findings were validated in Cre-absent df-Irs mice. The Tam-induced fat mass reduction could confound the effects of gene knockout, making it critical to allow for 6 weeks as a recovery period before further study is conducted. Note that the recovery period may vary with different animal models, thus warranting a deliberate determination for a specific laboratory model to establish a reliable experimental system.

The mechanism by which Tam reduces fat mass includes several cellular events. Tam treatment increased apoptosis and autophagy, the processes that reduce adipocyte number and have been implicated in adipose regulation.\(^2,^{18-23}\) Indeed, the cell density and population of mature adipocytes decreased after Tam treatment. Tam also promoted adipocyte dedifferentiation and ROS production, whereas normalization of ROS level markedly mitigated Tam-induced adipocyte dedifferentiation, apoptosis and autophagy, concomitant with restoration of mature adipocyte population and fat mass. Together, our data strongly suggest that the short-term (5-day) treatment with Tam reduces fat mass via boosting ROS production.

Tam was shown to induce ROS and oxidative stress in breast cancer cells, hepatoblastoma cells, retinal cells and platelets through activation of NAD(P)H oxidase, the enzyme that also promotes ROS production in macrophages.\(^32,42-46\) The ROS-boosting effect of Tam was extended and further validated by our study in adipocytes and adipose tissues. Importantly, we found that ROS elevation resulted in PPAR\(\gamma\) downregulation and adipocyte dedifferentiation, which support the notion that mature adipocytes undergo dedifferentiation under stress conditions.\(^34,35\) It was shown that proinflammatory adipocytokines (e.g., TNF\(\alpha\)) could promote adipocyte dedifferentiation through downregulation of PPAR\(\gamma\).\(^34,36\) Given that ROS elevation or oxidative stress increases TNF\(\alpha\) production,\(^47\) Tam may promote adipocyte dedifferentiation

Figure 5  Antioxidant NAC mitigates Tam effect on cell density and mature adipocyte population. (a–c) Microscopy imaging of 3T3L1 adipocytes treated with vehicle (a), 128 \(\mu\)M Tam (b) and Tam (128 \(\mu\)M) plus NAC (1 mM) (c). The microscope was set at \(\times\) 100. (d and e) Measurement of cell density and population of mature adipocytes using the NIH ImageJ software; \(n = 6-8\). *\(P < 0.05\)
by activating a ROS–TNFα–PPARγ axis. To this end, macrophage infiltration in adipose tissue might have a role, because these phagocytes were shown to instigate ROS and TNFα production and also respond sensitively to ROS- and TNFα-mediated signaling cascades.46,48

The effect of Tam on fat mass in humans, for example, breast cancer patients, remains inconclusive. Although Tam was reported to increase fat mass through its anti-estrogenic effect,13 recent studies loosened the conclusion by showing that Tam has no effect on the fat mass in breast cancer patients.14 It should be noted that the Tam dosage and treatment duration for mice in this study significantly differs from that for the long-term Tam treatment of breast cancer patients. To activate Cre recombinase to knock out target genes, animal models are typically treated for 5 consecutive days (administration of 1 mg/20 g body weight or 50–400 mg/kg body weight, once a day).8–12 However, Tam therapy for breast cancer patients in the United States generally lasts 5 years, with a dose of 20 mg (either one 20 mg tablet or two 10 mg tablets) taken by mouth once a day.49–51 Assuming that the body weight of breast cancer patients ranges from 50 kg to 80 kg, the average daily use of Tam would be 0.25–0.4 mg/kg, a dosage being 0.06–0.8% of that used in animal models. Owing to different dosage and treatment duration, the effect of Tam on mouse fat mass observed in this study might not be phenocopied in breast cancer patients with Tam therapy.

Figure 6 Countering or normalizing ROS reduced Tam effect on PPARγ. (a) Western blotting analysis (left panel) of PPARγ in 3T3L1 adipocytes after 48-h treatment with Tam (128 μM) or Tam (128 μM) plus NAC (1 mM), with densitometric analysis (right panel) of western blotting images using the NIH ImageJ software; n = 3–5. (b) At week 2 after Tam administration, western blotting (upper panel) was performed to analyze PPARγ, with densitometric analysis (lower panel) of western blotting images using the NIH ImageJ software; n = 3–5. (c) At week 6 after Tam administration, western blotting (upper panel) was performed to analyze PPARγ, with densitometric analysis (lower panel) of western blotting images using the NIH ImageJ software; n = 3–5. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was probed as a loading control. *P<0.05; **P<0.01

Materials and Methods

Materials. Dulbecco’s modified Eagle’s (DMEM) medium was from Corning Inc. (Manassas, VA, USA). Fetal bovine serum (FBS) was from GeneMate (North Logan, UT, USA). Dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), rosiglitazone and Tam were purchased from Cayman chemical (Ann Arbor, MI, USA). Penicillin/streptomycin (P/S) was from GE Healthcare Life Sciences HyClone Laboratories (Logan, UT, USA). Insulin and NAC were from Sigma-Aldrich (St. Louis, MO, USA). Phosphate-buffered saline (PBS) was from Caisson Laboratories, Inc. (North Logan, UT, USA).

Mice. The FoxO1 floxed mice (f-FoxO1) and Irs1/Irs2 double floxed mice (df-Irs) were bred and housed as previously described.15,16,52 Briefly, the mice were housed in plastic cages on a 12-h light–dark photocycle, with free access to water and regular chow diet. Before Tam treatment experiments, male mice (14–16-week old) were weighed, and fat mass was measured with a Bruker Minispec LF90 NMR Analyzer (Bruker Optics, Billerica, MA, USA). Then the mice were transferred to a biosafety level 2 (BSL2) room and administered with Tam (1 mg/20 g body weight) or the vehicle (sunflower oil) by I.P. injection (once a day for 5 consecutive days). After Tam administration, the cages were changed every 2 days until week 2, when the mice were transferred into BSL1 room, and the measurement of body fat mass was resumed. Depending on the experimental design, the mice were weighed and killed to harvest tissue for snap freezing in liquid nitrogen, at week 2 or week 6 after Tam treatment. All the procedures followed the NIH guideline and were approved by the Virginia Tech Institutional Animal Care and Use Committee.

Cell culture and treatment. 3T3L1 preadipocytes (ATCC CL-173, Manassas, VA, USA) were cultured in basal media (i.e., DMEM media supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin (1 x P/S)), at 37 °C in a humidified atmosphere of 5% CO2. The media were replaced every 2 days. Differentiation of 3T3L1 cells was induced as described previously with minor modifications.53 Briefly, 3T3L1 cells were grown to confluence (day 0) and maintained in fresh basal media (BMI) for 2 days (days 1–2). At the end of day 2,
BM1 medium was changed to differentiation medium I (DMI): DMEM supplemented with 10% FBS, P/S (1 x), IBMX (0.5 mM), dexamethasone (1 μM), insulin (1 μg/ml), and rosiglitazone (2 μM). At the end of day 4, DM1 medium was changed to differentiation medium II (DMII): DMEM supplemented with 10% FBS, P/S (1 x), and insulin (1 μg/ml). At the end of day 6, DMII medium was changed to basal media (BMII), and the cells were maintained in BMII (replaced with fresh basal medium every 2 days) until fully differentiated (day 12). As a control, preadipocytes were maintained in BMII till day 12 and supplied with fresh medium every other day. Upon full differentiation, 3T3L1 adipocytes were treated with Tam for 48 h at the concentrations of 0, 1, 6, 32, 64 and 128 μM and the vehicle 0.1% sunflower as a treatment control.12 When applicable, NAC was added at a concentration of 1 mM with Tam for a 48-h treatment to study the role of ROS.13 Images of the cells were captured on day 12 with a Nikon ECLIPSE TS100 microscope (Melville, NY, USA), and the cell counting and population analysis was conducted with the NIH ImageJ software (Bethesda, MD, USA).

ROS measurement. ROS in adipocytes and adipose tissue was measured as previously described.14,15 With a cell-permeable dye 5,6-carboxy-2',7'-dichloro-fluorescein diacetate (Carboxy-DCFDA, Molecular Probes, Grand Island, NY, USA). Snap-frozen adipose tissues were weighed and transferred into buffered medium (5 mMol/l HEPES in PBS) for quick thawing to improve the probe diffusion. After fluorescent diacetate (Carboxy-DCFDA, Molecular Probes, Grand Island, NY, USA) incubated in PLC lysis buffer:15,52 (30 mM Hepes, pH 7.5, 150 mM NaCl, 10% μM Na3VO4) supplemented with protease inhibitor cocktail (Roche, Branchburg, NJ, USA) and 1 mM PMSF, 10 μM Na3VO4, 1 mM Na2VO4) supplemented with protease inhibitor cocktail (Roche, Branchburg, NJ, USA) and 1 mM PMSF for 15 min at 4 °C. After homogenization, samples were centrifuged at 16 000 × g at 4 °C. Supernatants were collected and subjected to fluorescence analysis at 530 nm under excitation at 485 nm using a Synergy H4 Hybrid Multi-Mode Microplate Reader (BioTek Instruments, Winooski, VT, USA).

To measure ROS in 3T3L1 adipocytes, 1–5 × 106 cells were harvested with trypsin and washed three times with cold PBS, followed by incubation with 8 μM Carboxy-DCFDA in fresh medium and were incubated at 37 °C for 45 min under agitation. Medium was then removed, and samples were further incubated in a lysis buffer (0.1% SDS, Tris-HCl, pH 7.4) for 15 min at 4 °C. After homogenization, samples were centrifuged at 16 000 × g for 20 min at 4 °C. Supernatants were collected and subjected to fluorescence analysis at 530 nm under excitation at 485 nm using a Synergy H4 Hybrid Multi-Mode Microplate Reader (BioTek Instruments, Inc.). The ROS levels were normalized to the total protein for each cell dish.

Western blotting. To prepare tissue lysates, snap-frozen adipose tissues were weighed and homogenized with a Bullet Blender (Next Advance, Averill Park, NY, USA) in PLC lysis buffer supplemented with protease inhibitor cocktail (Roche, 1 mM PMSE, 10 μM TSA (Trichostatin A, Selleckchem, Houston, TX, USA) and 5 mM Nicotinamide (Alfa Aesar, Ward Hill, MA, USA)). For cell lysates, the 3T3L1 adipocytes were washed with ice-cold PBS and homogenized with a Bullet Blender. Total protein concentrations of the lysates were determined using the DC protein assay (Bio-Rad, Hercules, CA, USA) on a Synergy H4 Hybrid Multi-Mode Microplate Reader (BioTek Instruments, Inc.).

Statistical analyses. All results are expressed as means ± S.D. and are analyzed by analysis of variance to determine P values; P < 0.05 was considered statistically significant.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. We thank Dr. Ronald Depinho (University of Texas MD Anderson Cancer Center) and Dr. Morris F White (Children’s Hospital Boston, Harvard Medical School) for providing the FoxO1 and Δ-nras mice, respectively. Funding for this work was provided, in part, by the Virginia Agricultural Experiment Station and the Hatch Program of the National Institute of Food and Agriculture, US Department of Agriculture (to ZC), and by grant 1R01AT007077 from the National Center for Complementary and Alternative Medicine in the National Institutes of Health (to DL). Publication of this article was supported by Virginia Tech’s Open Access Subvention Fund.

1. Cheng Z, Almeida FA. Mitochondrial alteration in type 2 diabetes and obesity: an epigenetic link. Cell Cycle 2014; 13: 890–897.
2. Wang QA, Tao C, Gupta RK, Scherer PE. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat Med 2013; 19: 1338–1344.
3. Ogden CL, Carroll MD, Kib DK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA 2014; 311: 806–813.
4. Cawley J, Meyerhofer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ 2012; 31: 219–230.
5. Newender K. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes Obes Metab 2010; 12: 267–287.
6. Kanasaki K, Koya D. Biology of obesity: lessons from animal models of obesity. J Biomed Biotechnol 2011; 17: 97636.
7. Nilsson C, Raun K, Yan FF, Larsen MO, Tang-Christensen M. Laboratory animals as surrogate models of human obesity. Acta Pharmaco Sin 2012; 33: 173–181.
8. Feil S, Valtcheva N, Feil R. Inducible Cre mice. Methods Mol Biol 2009; 530: 343–363.
9. Li M, Indra AK, Ward X, Brocard J, Messaddeq N, Kato S et al. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 2007; 403: 633–636.
10. Reinert RB, Kantz J, Mielke AA, Poffenberger G, Gannon M, Brissau M et al. Tamoxifen-induced Cre-loxP recombination is prolonged in pancreatic islets of adult mice. Proc Natl Acad Sci USA 2012; 109: e33592.
11. Sassmann A, Offenmann S, Wetscherek N. Tamoxifen-inducible Cre-mediated recombination in adipocytes. Genesis 2010; 48: 618–625.
12. Imal T, Jiang M, Chambon P, Metzger D. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes. Proc Natl Acad Sci USA 2001; 98: 224–228.
13. Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 2001; 25: 296–298.
14. Franchini G, Petrioli R, Montagnani A, Cadrini A, Campagna S, Franchini E et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 2006; 95: 153–158.
15. Cheng Z, Guo S, Cops K, Dong X, Kolipara R, Rodgers JT et al. FoxO1 integrates insulin signaling with mitochondrial function in the liver. Nat Med 2009; 15: 1307–1311.
16. Dong XC, Cops KD, Guo S, Li Y, Kolipara R, Depinho RA et al. Inactivation of hepatic FoxO1 by insulin signaling is required for adaptive nutrient homeostasis and endothelial growth metabolism. Cell Metab 2008; 7: 65–76.
17. Paik JH, Kolipara R, Chu G, JH, Xiao, Ying Z et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007; 128: 309–323.
18. Yen WC, Bierer BE, McKnight SL. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci USA 1995; 92: 11086–11090.
19. Bell A, Grunder L, Sorisky A. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res 2000; 8: 249–254.
20. Polak P, Cybulski N, Feige JN, Auwers J, Ruegg MA, Hall MN. Adipocyte-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 2008; 8: 399–410.
21. Pattigows S, Bauvy C, Levade T, Levine B, Cotogno P. Ceramide-induced autophagy: to junk or to protect cells? Autophagy 2009: 5: 558–560.
22. Gulliksen PS, Haasman DB, Dearg RO, Hartzell DL, Baile CA. Adipose tissue cellularity and apoptosis after intracerebroventricular injections of leptin and 21 days of recovery in rats. Int J Obes Relat Metab Disord 2003; 27: 302–312.
23. Della-Fera MA, Qian H, Baile CA. Adipocyte apoptosis in the regulation of body fat mass and obesity. J Agric Food Chem 2014; 62: 5390–5400.
24. Liu SY, Chen CL, Yang TT, Huang WC, Heih CY, Shen WJ et al. Albinum prevents reactive oxygen species-induced mitochondrial damage, autophagy, and apoptosis during serum starvation. Apoptosis 2012; 17: 1156–1169.
25. Ghavami S, Eshragi M, Ande SR, Chazin WJ, Klonisch T, Halayko AJ et al. S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves NBI3P. Cell Res 2010; 20: 314–331.
Tamoxifen in obesity

L Liu et al

29. Poss KD, Tongeaws S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA 1997; 94: 10925–10930.

30. Hirao W, Ikematsu K, Tuda R. Age-associated increases in heme oxygenase-1 and ferritin immunoreactivity in the autopsied brain. Leg Med (Tokyo) 2003; 3: S360–S366.

31. Lavrovsky Y, Song CS, Chatterjee S, Roy AK. Age-dependent increase of heme oxygenase-1 gene expression in the liver mediated by NF-kappaB. Mech Ageing Dev 2000; 114: 49–60.

32. Cho KS, Yoon YH, Choi JA, Lee SJ, Kim JY. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells. Invest Ophthalmol Vis Sci 2012; 53: 5344–5353.

33. Suzuki YJ, Tsujiyoh M, Packer L. Thiocitic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic Res Commun 1997; 15: 255–263.

34. Zhang B, Berger J, Lu E, Szalkowski D, White-Carrington S, Spiegelman BM et al. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol 1996; 10: 1457–1468.

35. Xing H, Northrop JP, Grove JR, Kilpatrick KE, Su JL, Ringold GM. TNF alpha-mediated inactivation and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression. Endocrinology 1997; 138: 2776–2783.

36. De Paauw A, Tejernia S, Raes M, Keijer J, Arnold T. Mitochondrial (de)differentiation in adipocyte (de)differentiation and systemic metabolic alterations. Am J Pathol 2009; 175: 927–939.

37. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Endocrinology 1998; 13: 507–514.

38. Tenen D, Bruban V, Zhou L, Gong W, El Ashor Z, May P et al. LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J Biol Chem 2009; 284: 381–388.

39. Imai T, Takaiwka R, Marchand S, Dentz E, Bornert JM, Messaddeq N et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA 2004; 101: 4543–4547.

40. Dalil-Yocul N, Mataki C, Coste A, Messaddeq N, Giroud S, Blanc S et al. Adipose tissue-specific inactivation of the retinoblastoma protein protects against diabetes because of increased energy expenditure. Proc Natl Acad Sci USA 2007; 104: 10703–10708.

41. Konishi M, Nakamura H, Miwa H, Chambon P, Ornitz DM, Itoh N. Role of Fgf receptor 2c in adipocyte hypertrophy in mesenteric white adipose tissue. Mol Cell Endocrinol 2008; 287: 13–19.

42. Shah VP, Chegini HA, Vishneski SR, Weatherman RV, Blackmore PF, Dobrydenya Y. Tamoxifen promotes superoxide production in platelets by activation of PI3-kinase and NADPH oxidase pathways. Thromb Res 2012; 129: 36–42.

43. Kallio A, Zheng A, Dallalun J, Heikkanen KM, Harkonen P. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005; 10: 1395–1406.

44. Bursch W, Ellinger A, Kienz H, Torok L, Pandey S, Sikorska M et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996; 17: 1595–1607.

45. Lee YS, Kang YS, Lee SH, Kim JA. Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ 2000; 7: 925–932.

46. Forman HJ, Torres M. Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002; 166: 54–58.

47. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciottoli M et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067–2072.

48. Parameswaran N, Patil S. Tumor necrosis factor-alpha signaling in macrophages. Curr Rev Eukaryot Gene Expr 2010; 20: 87–103.

49. Fischer B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 473–484.

50. Gai MH, Costantino JP, Bryant J, Croyte L, Freedman L, Helzlsouer K et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1820–1846.

51. Reis SE, Costantino JP, Winkerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001; 93: 16–21.

52. Guo S, Copp KD, Dong X, Park S, Cheng Z, Pocias A et al. The IRS1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 2009; 29: 5070–5083.

53. Zebisch K, Voigt V, Wabitsch M, Brandsch M. Protocol for effective differentiation of 3T3-L1 adipocytes. J Vis Exp 2011; 59: 255.

54. Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X et al. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest 2011; 121: 4070–4081.

55. Benani A, Troy S, Carmona MC, Fioramonti X, Lorsignol A, Leloup C et al. Role for mitochondrial reactive oxygen species in brain lipid sensing: redox regulation of food intake. Diabetes 2006; 55: 152–160.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)